DiaSorin shares plunge 17% as 2026 margin outlook shadows FY25 earnings

Net profit fell 20% to €150m, and shares plunged 17% to a 10-year low after DiaSorin warned of flat-to-lower margins for 2026. Revenue rose 1% to €1.20bn (4% at constant FX) and adjusted EBITDA held at €394m (33% margin), while free cash flow dropped to €209m; the group recognised ~€20m of restructuring charges tied to closing its Shanghai plant. The board proposed a €1.30/share dividend (+8.3%) and authorised up to €250m buybacks; 2026 guidance targets 5–6% revenue growth at constant FX and a 32–33% adjusted EBITDA margin, excluding possible Middle East conflict impacts. Net financial debt eased to €580m from €618m.

Analysis

Market reaction to the company’s latest update looks driven less by one-off items and more by a reassessment of structural exposure: concentration in regional end-markets and a manufacturing footprint that’s now a lever for both cost and operational risk. That creates a two-way dynamic — near-term EPS support from capital returns can compress reinvestment, raising medium-term execution risk if demand normalizes unevenly across geographies.

Competitively, firms with redundant global capacity and diversified reagent/supply chains will win share if buyers prioritize resilience over price; conversely, vendors and distributors tied to the affected regions face multi-quarter revenue erosion as buyers migrate. Expect contract manufacturers and European-headquartered diagnostics majors to be incremental beneficiaries via both outsources and tender wins, amplifying relative outperformance versus single-market specialists.

Key catalysts over the next 3–9 months are sequencing: (1) order flow out of the US flu/respiratory cycle, which will re-rate growth expectations; (2) any measurable stabilization or disruption in cross-border logistics that alters lead times and input costs; and (3) quarterly margin prints relative to revised guidance that either validate or reverse the de-risking narrative. Tail risk remains geopolitical escalation that can amplify supply disruptions and force a premium on inventory/dual sourcing — a capital-intensive remedy that would compress returns for a prolonged period.

Key Decisions for Investors

• Short DIAS (equity or buy a 3–6 month put spread) vs long Roche (RHHBY) as a hedge — target 20–30% downside in DIAS relative to Roche over 3–9 months; cap premium outlay to 2–4% of notional to preserve asymmetric payoff if margins miss again.
• Pair trade: long a European contract manufacturer (e.g., LZAGY/Lonza) and short DIAS — thesis: outsourcing demand and pricing power shift to larger CMOs if single-company supply risk persists; horizon 6–12 months, stop-loss if DIAS reports margin expansion >100bps quarter-over-quarter.
• Buy selective long exposure to US-based diagnostics/CLIA leaders (e.g., ABT/Abbott) for 12–18 months to capture any market-share migration and higher-margin specialty test growth; consider funded purchases (sell OTM calls) to improve entry economics.
• Monitor for event-driven entry: if DIAS executes a sizeable buyback plus sustained margin improvement in two consecutive quarters, convert short position to a modest long (take profits on shorts at 50% of position) — this is the primary reversal trigger to flip stance.